2022-RA-447-ESGO Efficacy and safety of VB10.16, a therapeutic DNA vaccine specifically targeting antigen-cell presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer: results from a pre-planned interim analysis
P. Hillemanns, K. Lindemann, J. Baurain, P. Blecharz, K. B. Slot, K. Schjetne, S. Torhaug, A. Fredriksen
{"title":"2022-RA-447-ESGO Efficacy and safety of VB10.16, a therapeutic DNA vaccine specifically targeting antigen-cell presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer: results from a pre-planned interim analysis","authors":"P. Hillemanns, K. Lindemann, J. Baurain, P. Blecharz, K. B. Slot, K. Schjetne, S. Torhaug, A. Fredriksen","doi":"10.1136/ijgc-2022-esgo.26","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"33 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cervical cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-esgo.26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
